XERS Straddle Strategy
XERS (Xeris Biopharma Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS (Xeris Biopharma Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.11B, a trailing P/E of 91.31, a beta of 0.92 versus the broader market, a 52-week range of 4.3-10.08, average daily share volume of 1.9M, a public-listing history dating back to 2018, approximately 394 full-time employees. These structural characteristics shape how XERS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.92 places XERS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 91.31 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a straddle on XERS?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current XERS snapshot
As of May 15, 2026, spot at $6.29, ATM IV 64.90%, IV rank 24.44%, expected move 18.61%. The straddle on XERS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on XERS specifically: XERS IV at 64.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a XERS straddle, with a market-implied 1-standard-deviation move of approximately 18.61% (roughly $1.17 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XERS expiries trade a higher absolute premium for lower per-day decay. Position sizing on XERS should anchor to the underlying notional of $6.29 per share and to the trader's directional view on XERS stock.
XERS straddle setup
The XERS straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XERS near $6.29, the first option leg uses a $6.29 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XERS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XERS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.29 | N/A |
| Buy 1 | Put | $6.29 | N/A |
XERS straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
XERS straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on XERS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on XERS
Straddles on XERS are pure-volatility plays that profit from large moves in either direction; traders typically buy XERS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
XERS thesis for this straddle
The market-implied 1-standard-deviation range for XERS extends from approximately $5.12 on the downside to $7.46 on the upside. A XERS long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current XERS IV rank near 24.44% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XERS at 64.90%. As a Healthcare name, XERS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XERS-specific events.
XERS straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XERS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XERS alongside the broader basket even when XERS-specific fundamentals are unchanged. Always rebuild the position from current XERS chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on XERS?
- A straddle on XERS is the straddle strategy applied to XERS (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With XERS stock trading near $6.29, the strikes shown on this page are snapped to the nearest listed XERS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are XERS straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the XERS straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 64.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a XERS straddle?
- The breakeven for the XERS straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XERS market-implied 1-standard-deviation expected move is approximately 18.61%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on XERS?
- Straddles on XERS are pure-volatility plays that profit from large moves in either direction; traders typically buy XERS straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current XERS implied volatility affect this straddle?
- XERS ATM IV is at 64.90% with IV rank near 24.44%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.